• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-A12B filed by Eloxx Pharmaceuticals Inc.

    6/1/26 5:26:12 PM ET
    $ELOX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ELOX alert in real time by email
    8-A12B 1 d75472d8a12b.htm 8-A12B 8-A12B
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-A

     

     

    FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

    PURSUANT TO SECTION 12(b) OR (g) OF

    THE SECURITIES EXCHANGE ACT OF 1934

     

     

    ELOXX PHARMACEUTICALS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   84-1368850
    (State of incorporation or organization)   (I.R.S. Employer Identification No.)

    P.O. Box 274

    Arlington, MA

      02476
    (Address of Principal Executive Offices)   (Zip Code)

    Securities to be registered pursuant to Section 12(b) of the Act:

     

    Title of each class

    to be so registered

     

    Name of each exchange on which

    each class is to be registered

    Common Stock, $0.01 par value per share   The Nasdaq Stock Market LLC

     

     

    If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box: ☒

    If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box: ☐

    If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐

    Securities Act registration statement or Regulation A offering statement file number to which this form relates:

    333-295651

    Securities to be registered pursuant to Section 12(g) of the Act:

    None

     

     
     


    Item 1. Description of Registrant’s Securities to be Registered.

    A description of the common stock, $0.01 par value per share, of Eloxx Pharmaceuticals, Inc., a Delaware corporation (the “Registrant”), to be registered hereunder is contained in the section entitled “Description of Capital Stock” in the prospectus that constitutes part of the Registrant’s Registration Statement on Form S-1 (File No. 333-295651) initially filed with the Securities and Exchange Commission (the “SEC”) on May 7, 2026, including exhibits, and as amended from time to time (the “Registration Statement”), and is incorporated herein by reference. Any form of prospectus subsequently filed by the Registrant with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended, that constitutes part of the Registration Statement shall be deemed to be incorporated herein by reference.

    Item 2. Exhibits.

    Pursuant to the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed with this registration statement because no other securities of the Registrant are registered on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.


    SIGNATURE

    Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

     

    Dated: June 1, 2026     ELOXX PHARMACEUTICALS, INC.
        By:   /s/ Sumit Aggarwal
        Name:   Sumit Aggarwal
        Title:   President and Chief Executive Officer
    Get the next $ELOX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELOX

    DatePrice TargetRatingAnalyst
    12/17/2021$4.00Outperform
    Oppenheimer
    11/18/2021$2.00 → $1.00Neutral
    HC Wainwright & Co.
    11/11/2021$3.00 → $2.00Neutral
    HC Wainwright & Co.
    6/30/2021$3.10Buy
    Mizuho
    More analyst ratings

    $ELOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Eloxx Pharmaceuticals with a new price target

    Oppenheimer initiated coverage of Eloxx Pharmaceuticals with a rating of Outperform and set a new price target of $4.00

    12/17/21 5:45:41 AM ET
    $ELOX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HC Wainwright & Co. reiterated coverage on Eloxx Pharmaceuticals with a new price target

    HC Wainwright & Co. reiterated coverage of Eloxx Pharmaceuticals with a rating of Neutral and set a new price target of $1.00 from $2.00 previously

    11/18/21 6:16:16 AM ET
    $ELOX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HC Wainwright & Co. reiterated coverage on Eloxx Pharmaceuticals with a new price target

    HC Wainwright & Co. reiterated coverage of Eloxx Pharmaceuticals with a rating of Neutral and set a new price target of $2.00 from $3.00 previously

    11/11/21 6:39:05 AM ET
    $ELOX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELOX
    SEC Filings

    View All

    Amendment: SEC Form S-1/A filed by Eloxx Pharmaceuticals Inc.

    S-1/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)

    6/4/26 5:17:04 PM ET
    $ELOX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-A12B filed by Eloxx Pharmaceuticals Inc.

    8-A12B - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)

    6/1/26 5:26:12 PM ET
    $ELOX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form S-1/A filed by Eloxx Pharmaceuticals Inc.

    S-1/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)

    6/1/26 4:55:29 PM ET
    $ELOX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELOX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Webster Stephen W

    3 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)

    6/1/26 7:00:05 AM ET
    $ELOX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Kjellson Nina S

    3 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)

    6/1/26 7:00:03 AM ET
    $ELOX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Coastlands Capital Lp disposed of 1,250,000 shares (SEC Form 4)

    4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)

    5/29/26 9:55:45 PM ET
    $ELOX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELOX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Eloxx Pharmaceuticals Announces Key Corporate Accomplishments

    Data from Eloxx's proof-of-concept trial in patients with nonsense mutation Alport Syndrome (NMAS) presented in late-breaking presentation at American Society of Nephrology (ASN) Kidney Week New protein analyses confirm production of both collagen alpha 4 and collagen alpha 5 in patients post treatment with ELX-02 Results justify the need to conduct a larger clinical trial of ELX-02 in NMAS to confirm clinical benefit U.S. Food and Drug Administration (FDA) allows for continued dosing of subjects in Phase 1 trial of ZKN-013 WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (OTC:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases w

    11/12/24 4:05:00 PM ET
    $ELOX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Eloxx Pharmaceuticals Provides Pipeline and Financing Updates

    First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations Positive written FDA feedback and guidance from a pre-Investigational New Drug Application (PIND) meeting provides pathway to IND application submission to initiate a Phase 2 clinical trial in the US with ELX-02 in patients with nonsense mutation alport syndrome (NMAS) Secured binding commitment for additional $3.2 million financing to advance our clinical programs WATERTOWN, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (OTC:ELOX), a leader in ribosomal RNA-targeted gene

    7/11/24 11:46:35 AM ET
    $ELOX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates

    ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome Pre-Investigational New Drug (IND) Meeting Requested with U.S. FDA for ELX-02 to Discuss Planned next Study In Nonsense Mutation Alport Syndrome Signed Global Licensing Partnership for ZKN-013 with Almirall Pharmaceuticals with $3M upfront and up to $470M in milestones and Tiered Royalties on Global Sales New Paper Published on Autosomal Dominant Polycystic Kidney Disease (ADPKD) shows that ELX-02 treatment prevents cyst formation in diseased PKD organoids with nonsense mutations and a single healthy gene copy WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWI

    4/16/24 7:30:00 AM ET
    $ELOX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELOX
    Leadership Updates

    Live Leadership Updates

    View All

    Cognito Therapeutics Appoints Greg Weaver as Chief Financial Officer

    Cognito Therapeutics, a pioneer developing disease-modifying therapeutics to treat CNS diseases, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), to lead all finance-related and investor relations functions at the Company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017630946/en/Greg Weaver, CFO, Cognito Therapeutics (Photo: Business Wire) Mr. Weaver is a highly accomplished finance executive who brings more than 30 years of life sciences, financial and operations experience to Cognito. Most recently, he served as CFO of Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage oncology comp

    10/17/23 8:00:00 AM ET
    $ATAI
    $ATOS
    $ELOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer

    SEATTLE, June 01, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focus on breast cancer, today announces the appointment of Greg Weaver as the Company's new Chief Financial Officer (CFO). Mr. Weaver succeeds Kyle Guse. A short video interview with Mr. Weaver about his background and vision for Atossa can be found here: https://youtu.be/G6ZzHLh-qsQ Mr. Weaver brings more than 30 years of life sciences, financial and operations experience to the Company. Recently, he served as CFO of privately held BioIntelliSense, a commerc

    6/1/23 9:10:00 AM ET
    $ATAI
    $ATOS
    $ELOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Eloxx Pharmaceuticals Announces Changes to Board of Directors

    Lindsay Androski, JD, MBA brings significant experience growing biotech companies through her roles as an executive at Roivant Social Ventures Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seehra step down from the Eloxx board WATERTOWN, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the appointment of Lindsay Androski, JD, MBA to its board of directors and as a member of the Board's Audit Committee and Compensation Committee. Current board members Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr.

    7/5/22 8:00:00 AM ET
    $ELOX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELOX
    Financials

    Live finance-specific insights

    View All

    Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

    Combination of subcutaneous ELX-02 with ivacaftor did not achieve statistical significance for efficacy endpoints in Phase 2 study in Class 1 CF ELX-02 was well tolerated with no drug-related serious adverse events observed Evidence of activity for ELX-02 observed; efficacy signal potentially confounded by variability due to low drug exposure Path forward for ELX-02 for the treatment of Class 1 CF to be determined together with CF Foundation Company to host conference call and webcast today, September 14, 2022, at 4:30 p.m. ET WATERTOWN, Mass., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare d

    9/14/22 4:05:00 PM ET
    $ELOX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients

    ELX-02 monotherapy dosed at 1.5mg/kg/day demonstrated a statistically significant 5.4mmol/L mean sweat chloride reduction, an established surrogate for restoration of CFTR biological activity ELX-02 monotherapy results support advancement of ELX-02 into Phase 3 clinical development First patient dosed in Phase 2 ELX-02 expansion treatment arms evaluating combination with ivacaftor; topline data expected by the end of the first half of 2022 Company to host conference call and webcast Wednesday, November 17, 2021 at 8:30 am ET WATERTOWN, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare dise

    11/17/21 7:00:00 AM ET
    $ELOX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Eloxx Pharmaceuticals Acquires Zikani Therapeutics

    Combined Company to be Leader in Ribosomal RNA-Targeted Genetic Therapy Bringing Together Complementary Platforms Maximizes Potential for ELX-02 for Cystic Fibrosis in Phase 2 Development Adds Preclinical Stage Pipeline in Rare Diseases and Oncology Targeting RNA and Ribosomal Mutations Expects to File IND for First Oral Drug to Treat Patients with Recessive Dystrophic and Junctional Epidermolysis Bullosa (RDEB and JEB) Sumit Aggarwal, Zikani President and CEO, to Lead the Combined Company Eloxx to Issue Approximately 7.6 Million Shares to Zikani Stockholders Company to Host Investor Call at 8:30 a.m. ET, April 1 WALTHAM, Mass. and WATERTOWN, Mass., April 01, 2021 (GLOBE NEWSWIRE

    4/1/21 7:45:00 AM ET
    $ELOX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Eloxx Pharmaceuticals Inc.

    SC 13D/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)

    8/20/24 8:13:16 PM ET
    $ELOX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Eloxx Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)

    2/13/23 4:52:16 PM ET
    $ELOX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Eloxx Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)

    2/14/22 6:18:22 AM ET
    $ELOX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care